Mainz Biomed (MYNZ) has entered into a technology partnership with UK-based EDX Medical Group, which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed’s molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed provides Q1 update, path to FDA premarket approval
- Mainz Biomed Reports 2024 Financial Success and Strategic Advances
- Mainz Biomed reports FY24 EPS ($22.36) vs ($64.76) last year
- Buy Rating for Mainz Biomed B.V. Driven by Promising CRC Screening Advancements and Strategic Partnerships
- Mainz Biomed enrolls first patient in its eAArly DETECT 2 study